En savoir plus sur le service recherche clinique (Pr Jean-Pierre Delord) de l'IUCT-Oncopole avec le reportage 'In Vivo'  (France 5).



Chiffres clefs


201 essais cliniques ayant inclus des patients en 2019

1 651 patients de l'IUCT-Oncopole inclus dans un essai soit 16% de la file active.

56,21 % d'essais de phases précoces


General information website 

notre-recherche-clinique.fr




List of ICR-IUCT-O clinical trials  

Via clinicaltrials.gov 

 


Recherches nécessitant une réutilisation de données


La nouvelle réglementation en vigueur applicable au traitement de données à caractère personnel et, en particulier, le règlement UE 2016/679 du Parlement européen et du Conseil du 27 avril 2016 (ci-après le « RGPD ») a pour objectif de renforcer la maîtrise des personnes sur les données les concernant.

Les personnes prises en charge dans le cadre de l’activité de l’Institut doivent être informées du traitement de données personnelles les concernant (art. 14 RGPD). Les patients sont autorisés à demander à l’Institut la communication des données recueillies et à exercer leurs droits de modification, de correction, de mise à jour ou d’effacement de ces données.

En savoir plus


Clinical Research Approval


The clinical trials administrative center is ISO 9001:2008 certified for the design and management of clinical trials in oncology.
See the certificate

The Clinical Research Unit is an INCa-designated early-phase clinical trial center.


Clinical research

L'IUCT Oncopole réalise en moyenne 180 essais cliniques par an (essais actifs yanat inclus des patients dans l'année).

The IUCT Oncopole and Purpan IUCT, Rangueil-Larrey IUCT and CRCT carry out an average of 400 clinical trials per year.
Many molecules are left out in the late stages of their development. This therefore requires the development of approaches able to detect, at the earliest stages (preclinical and clinical), the inefficacy or even toxicity of molecules developed for clinical use.
The efficacy of treatments varies from one type of cancer to another and, for the same type of cancer, from one patient to another, without us being able properly to foresee this.

For optimum efficacy and minimal toxicity, targeted drugs need to be offered to patients   in whom the presence or absence of biomarkers in the blood can predict the therapeutic response. Therapeutic approaches have thus become increasingly "personalized".

 

The objectives of clinical research should be:

  • improvement of patient survival;
  • optimization of treatment;
  • de-escalation of therapy to reduce side effects and delayed effects.

 

At the IUCT Oncopole, 13% of patients are asked if they want to be included in a clinical research protocol. The medium-term goal is to reach 15%.
All the early phase trials are carried out at the IUCT Oncopole regardless of the type of cancer and the place where the patient is treated (IUCT   Oncopole, Rangueil-Larrey IUCT, Purpan IUCT, general hospitals in the Midi-Pyrénées region, private clinics).

The phase III and IV  clinical trials performed at the IUCT-Oncopole concern diseases treated at the institute (hematology, senology, gynecology, melanomas, etc.). For other specialties such as liver, gastric and gastrointestinal cancers, the  trials are conducted at Purpan IUCT and Rangueil IUCT.

 

Platforms and expertise 

1) an INCa-designated early-phase clinical trial center (CLIPP),  one of the 16 French centers specialized in early phase clinical trials of innovative therapies in oncology.

2) an ISO 9001:2015 certified clinical research administrative center

3) a pharmacology unit which in addition to basic research, provides pharmacological monitoring for the clinical trials of all new medicinal products.

4) a preclinical phase platform. On a single site, (on the 1st floor of the CRCT building, the Regional Center for Functional Exploration and Experimental Resources (CREFRE) will group together all the animal husbandry, transgenesis and functional investigation services : microsurgery, phenotyping, non-invasive explorations, histopathology), it will be possible to test a molecule or a therapeutic approach from the preclinical phases to the later phases.